The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.
 
Bennett Adam Caughey
No Relationships to Disclose
 
Kumiko Umemoto
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
 
Michelle Green
Employment - N-of-One
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from SciMed
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Ono Pharmaceutical; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Rachel D'Anna
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; AstraZeneca (Inst); Chugai Pharma; Delta-Fly Pharma; Eisai (Inst); Incyte (Inst); JPH Clinical Development; Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Donna Niedzwiecki
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Daniel Walden
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Katherine I. Zhou
No Relationships to Disclose
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Dainippon Pharma (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst)
 
Ryne Ramaker
No Relationships to Disclose
 
Tadamichi Denda
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Daiichi-Sankyo; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Michael Datto
Research Funding - Foundation Medicine (Inst)
Patents, Royalties, Other Intellectual Property - MRT is intellectual property for which I am the 'inventor'. This software is licensed through Duke.
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
John H Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera (Inst); Pfizer; Pionyr; Roche/Genentech (Inst); Seagen; Silverback Therapeutics; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Exelixis (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)